BridgeBio Pharma price objective cut to $102 from $104
BBIO•BofA Global Research cut its price objective for BridgeBio Pharma to $102 from $104.
Related News
Axcelis Technologies target price cut to $165 from $198
ACLS•
Curaleaf Holdings challenges Aurora's unilateral rejection of its enhanced proposal
ACB•
SL Green secures $2 billion CMBS refinancing for 245 Park Avenue
SLG•
Valor Energy enters agreement to acquire 18MW computing center in Youngstown, Ohio
VAI•
Marathon Petroleum Corporation: Raymond James raises target price to $560 from $445
MPC•